Opus Genetics (IRD) Net Equity Issued and Repurchased (2011 - 2026)

Opus Genetics (IRD) has 13 years of Net Equity Issued and Repurchased data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased rose 450.12% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $4.5 million, a 25.86% decrease from a year earlier, with the FY2025 full-year figure at $5.8 million, up 29.09% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $2.2 million, up from $179000.0 in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for IRD reached as high as $5.2 million in Q3 2024 and fell as low as $28000.0 in Q4 2022.
• Historically, Net Equity Issued and Repurchased has averaged $1.9 million across 5 years, with a median of $1.5 million in 2022.
• Across the five-year window, Net Equity Issued and Repurchased tumbled 99.88% in 2022 and jumped 13275.0% in 2023, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $28000.0 in 2022, then soared by 13275.0% to $3.7 million in 2023, then jumped by 38.85% to $5.2 million in 2024, then sank by 96.56% to $179000.0 in 2025, then surged by 1156.98% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $2.2 million in Q1 2026, $179000.0 in Q4 2025, and $1.7 million in Q3 2025.